The FDA gives Fast Track Priority to uniQure’s Hemophilia B Gene Therapy – Labiotech.eu (blog)
|
The FDA gives Fast Track Priority to uniQure's Hemophilia B Gene Therapy
Labiotech.eu (blog) UniQure has received Breakthrough Therapy Designation from the FDA, granting fast track to its gene therapy for hemophilia B. UniQure is one of the companies leading the development of gene therapy for hemophilia. Now, the FDA has granted … uniQure Announces FDA Breakthrough Therapy Designation for AMT-060 in Hemophilia B |
